Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin as an Antifungal Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplant

NCT00606268 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00606268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00606268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin as an Antifungal Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplant
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
March 31, 2009
Enrollment
42 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

fungal infections